| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453807 | Lung Cancer | 2018 | 12 Pages |
Abstract
The loss of LIP mediates cisplatin resistance, rendering LIP a possible predictor of cisplatin response in MPM patients. The association of proteasome and lysosome inhibitors reverses cisplatin resistance by restoring LIP levels and may represent a new adjuvant strategy in MPM treatment.
Keywords
WT1ATF6IRE1HMCMPMSPSSqRT-PCRCHOP/GADD153TBSEMAtribbles-related protein 3UPNCAAT/enhancer binding proteinTRB3human mesothelial cellsC/EBPCeAPFsEpithelial membrane antigeninositol-requiring enzyme 1Endoplasmic reticulum stresschromatin immunoprecipitationStatistical Package for Social ScienceProgression free survivaloverall survivalanalysis of varianceANOVATris-buffered salineICDquantitative real time-PCRDendritic cellsendoplasmic reticulumactivating transcription factor 6Immunogenic cell deathMalignant pleural mesotheliomaCisplatin resistanceCHiP
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Joanna Kopecka, Iris C. Salaroglio, Luisella Righi, Roberta Libener, Sara Orecchia, Federica Grosso, Vladan Milosevic, Preeta Ananthanarayanan, Luisa Ricci, Enrica Capelletto, Monica Pradotto, Francesca Napoli, Massimo Di Maio, Silvia Novello,